Niagen Bioscience to Report Fiscal 2025 Results in March

Investors in Niagen Bioscience are set to receive a comprehensive review of the company’s performance when it reports its fourth-quarter and full-year 2025 financials. The bioscience firm has scheduled the release for Wednesday, March 4, 2026, after the close of U.S. markets. This disclosure will be critical for assessing whether the company has met its aggressive growth targets in the cellular health sector.

The upcoming report carries significant weight following a strong third quarter. For Q3 2025, Niagen posted revenue of $34 million, marking a 33 percent year-over-year increase. The company also reported a gross margin of 64.5 percent and net income of $4.6 million for the period.

Management has previously provided full-year 2025 revenue guidance, projecting growth between 25 and 30 percent. The March 4th announcement and subsequent conference call, scheduled for 10:30 p.m. CET, will reveal if the company achieved this target and sustained its momentum through the final quarter. The call will also offer insight into the outlook for the new fiscal year.

Strategic Initiatives Driving Growth

Niagen has implemented several key strategic moves aimed at expanding its market reach. A major development early in the year was enabling U.S. consumers to purchase its TRU NIAGEN supplement using tax-advantaged Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs). This initiative is designed to significantly improve product accessibility.

Should investors sell immediately? Or is it worth buying Niagen Bioscience?

The company is also aggressively expanding its distribution network. Sales channels now include major online platforms like Amazon, in addition to its direct e-commerce operations. Furthermore, Niagen has substantially increased its physical retail footprint; its products are now available in more than 800 wellness clinics across the United States, a notable jump from the 475 locations reported at the end of 2024.

Strengthening the Corporate Foundation

Beyond sales channels, Niagen has taken steps to fortify its long-term position. In December of the previous year, the company acquired an extensive patent portfolio related to Nicotinamide Riboside, bolstering its intellectual property estate.

This move was complemented by the launch of a $10 million share repurchase program in November. Together, these actions signal a focus on strengthening the company's foundational assets while returning value to shareholders.